Optimal Surgical Approach for Chronic Pancreatitis with Inflammatory Head Mass
Viêm tụy mạn là bài đọc thêm trong sách Bệnh học ngoại khoa YDS, vì sao ư, vì nó khó vãi ò từ cơ chế, bệnh sinh, chẩn đoán và quản lý. Thực tế lâm sàng mình gặp nhiều bệnh nhân viêm tụy mạn nhập viện với bệnh cảnh đau bụng dai dẳng, sụt cân, rối loạn đường huyết và việc điều chỉnh đường huyết đến lựa chọn phương pháp điều trị rất phức tạp. Nhân cơ hội được nghe sinh hoạt chuyên môn về vấn đề này, thôi thì tự tổng hợp sơ sơ về chọn lựa phương pháp phẫu thuật trong viêm tụy mạn với khối viêm đầu tụy.
- Khi gặp bệnh nhân viêm tụy mạn với khối viêm đầu tụy, yếu tố nào giúp lựa chọn giữa PD (cắt khối tá tụy) và DPPHR (cắt đầu tụy bảo tồn tá tràng)?
- Phẫu thuật sớm có khác biệt gì về cải thiện điểm đau và chất lượng sống so với chiến lược “nội soi trước, mổ sau” không?
- Lựa chọn DPPHR có giảm tỉ lệ suy tụy ngoại tiết-nội tiết và thiếu vi chất so với PD, về ngắn hạn và dài hạn?
- Nguy cơ về mặt ung thư học và biến chứng của PD và DPPHR khác biệt gì?
I. Surgical Options and Technical Considerations
Chronic pancreatitis with an inflammatory mass in the pancreatic head presents a complex surgical challenge, particularly when the primary clinical concerns are pain management and oncologic safety. The two principal surgical strategies are duodenum-preserving pancreatic head resection (DPPHR) and pancreaticoduodenectomy (PD, Whipple procedure), each with distinct technical features, indications, and implications for postoperative outcomes.
1. Duodenum-Preserving Pancreatic Head Resection (DPPHR)
DPPHR encompasses several techniques—most notably the Beger, Frey, and Berne procedures—designed to remove the inflammatory mass in the pancreatic head while preserving the duodenum, pylorus, and, typically, the common bile duct. The Beger procedure involves transection of the pancreas at the neck, resection of the pancreatic head, and reconstruction with two pancreaticojejunostomies. The Frey procedure cores out the pancreatic head and combines this with a longitudinal pancreaticojejunostomy, facilitating drainage of the entire gland. The Berne modification is similar to the Frey but omits the extended lateral drainage, focusing on coring out the head alone. These procedures are indicated for patients with chronic pancreatitis and a dominant inflammatory mass in the pancreatic head, especially when (1) pain is refractory to medical and endoscopic management and there is (2) no clear evidence of malignancy. The Frey and Beger procedures are particularly favored when the pancreatic head is enlarged (typically >40 mm) and the main pancreatic duct is dilated, as they address both the mass and ductal hypertension, which are key drivers of pain in this population.[1-5]
2. Pancreaticoduodenectomy (PD/Whipple)
Pancreaticoduodenectomy, including the classic Whipple and pylorus-preserving variants, involves resection of the pancreatic head, duodenum, and often the distal bile duct, with reconstruction of the gastrointestinal tract. This procedure is primarily indicated when there is a strong suspicion or confirmation of malignancy in the pancreatic head, as it allows for oncologically adequate resection with lymphadenectomy. PD may also be considered in cases of severe, refractory pain when other procedures are not feasible or have failed, or when the anatomy is not amenable to duodenum-preserving techniques. The American Gastroenterological Association and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition both emphasize that PD remains the operation of choice when malignancy is suspected.[2-3][6-7]
II. Comparative Outcomes: Pain, Oncologic Safety, and Function
A critical aspect of surgical decision-making in chronic pancreatitis with a pancreatic head mass is the comparative analysis of (1) pain relief, (2) oncologic safety, (3) preservation of pancreatic function, and (4) the risk of postoperative complications.
1. Pain Relief and Opioid Dependence
Both DPPHR and PD are highly effective in achieving long-term pain relief in patients with chronic pancreatitis and a pancreatic head mass. Meta-analyses and randomized trials consistently demonstrate that rates of complete or major pain relief range from 62% to 85% for both procedures, with no statistically significant difference in long-term outcomes.[5][8-15] For example, the ChroPac trial, a multicenter randomized controlled study, found no significant differences in pain, quality of life, or pancreatic function between PD and DPPHR at 24 months.[9] Similarly, the meta-analysis by Zhao et al. reported a risk ratio for pain relief of 1.09 (95% CI 0.94–1.25, P = 0.26) for DPPHR versus PD, indicating equivalent efficacy.[5]
Long-term opioid independence is a key outcome, given the risks of chronic opioid therapy. Turner et al. found that 67.7% of patients in the DPPHR group and 61.9% in the PD group remained opioid-free at long-term follow-up (P = 0.539), indicating similar effectiveness in reducing opioid dependence.[16] The rate of chronic pain recurrence and need for reoperation is low for both procedures, with DPPHR showing a redo surgery rate of approximately 7.6%.[17]
The importance of early surgical intervention is underscored by the ESCAPE trial, which demonstrated that early surgery (within 6 weeks of randomization) resulted in significantly lower integrated pain scores over 18 months compared to an endoscopy-first approach (mean Izbicki pain score 37 vs 49; between-group difference −12 points, 95% CI −22 to −2; P = .02).[18] The long-term follow-up of the ESCAPE cohort confirmed the durability of these benefits, with a higher proportion of patients reporting complete pain relief and greater satisfaction in the early surgery group.[19]
2. Oncologic Outcomes and Malignancy Risk
The risk of missed malignancy is a central concern in the surgical management of chronic pancreatitis with a pancreatic head mass. Chronic pancreatitis is associated with an increased risk of pancreatic ductal adenocarcinoma, and surgical resection for presumed benign disease may incidentally uncover malignancy in up to 7% of cases.[20-21] Pancreaticoduodenectomy offers the highest oncologic safety, with complete resection and lymphadenectomy, and is indicated when malignancy is suspected based on imaging, cytology, or clinical features.[2-3][6-7][22]
Duodenum-preserving pancreatic head resection is preferred when the probability of malignancy is low or moderate, as it provides equivalent pain relief and long-term survival with lower morbidity and better preservation of function.[5][9][12-13][23-27] Meta-analyses show that DPPHR achieves oncologically complete resection for benign and premalignant lesions, with recurrence rates and disease-specific survival comparable to PD. For example, Beger et al. reported a 5-year disease-specific survival of 97.3% after DPPHR for cystic neoplasms and neuroendocrine tumors, with a recurrence rate of 4.1% for IPMN/MCN and 2.2% for PNET.[27] The risk of postoperative development of pancreatic cancer in the remnant pancreas after DPPHR for a benign inflammatory mass is exceedingly low, provided that the initial lesion is completely resected and there is no evidence of high-grade dysplasia or invasive carcinoma on final pathology.[27-30]
When imaging and biopsy are inconclusive for malignancy, guideline-based multidisciplinary assessment is essential. The American Society of Clinical Oncology recommends that surgical decisions be made by experienced clinicians in a multidisciplinary setting, integrating all available clinical, radiologic, and pathologic data.[22]
3. Pancreatic Function and Nutritional Outcomes
Preservation of pancreatic exocrine and endocrine function is a major advantage of DPPHR over PD, particularly in the short- and medium-term. Meta-analyses and cohort studies demonstrate that DPPHR is associated with significantly lower rates of new onset exocrine insufficiency (6.7–28% short-term) and endocrine insufficiency (5–15.7% short-term) compared to PD (44.9–76.5% and 14.5–34.3%, respectively).[5][16][25-26][33] However, long-term rates of insufficiency tend to converge due to the progressive nature of chronic pancreatitis, with both procedures showing high rates of exocrine (62–87.5%) and endocrine (18.6–87%) insufficiency at extended follow-up.[13-14][34]
Nutritional deficiencies, particularly in fat-soluble vitamins (A, D, E, K), iron, and zinc, are common after PD due to the loss of duodenal and proximal jejunal absorptive capacity and the high incidence of pancreatic exocrine insufficiency. Vitamin D deficiency occurs in up to 79% of patients after PD, and iron deficiency in 42%, despite routine supplementation.[35-37] DPPHR, by preserving the duodenum and maintaining more physiological gastrointestinal continuity, is associated with a lower risk of severe malabsorption, but patients remain at risk for deficiencies due to underlying disease.[38] The International Study Group on Pancreatic Surgery recommends routine assessment and management of exocrine insufficiency, early initiation of pancreatic enzyme replacement therapy (PERT), and targeted supplementation of vitamins and minerals for all patients undergoing pancreatic head resection.[38-39]
4. Postoperative Complications
The risk of major postoperative complications is a key consideration in surgical planning. DPPHR is associated with lower or comparable rates of pancreatic fistula, significantly lower incidence of delayed gastric emptying, reduced surgical infection rates, shorter hospital stays, and lower severe morbidity and mortality compared to PD.[5][12][23-24][40-51] For example, the incidence of delayed gastric emptying after PD ranges from 13% to 38%, while DPPHR is associated with a markedly decreased risk (relative risk 0.11 vs PD; P ≤ 0.01).[40][45-49][51] In-hospital mortality after PD is approximately 3–4% in large national audits, while DPPHR is associated with very low perioperative mortality, often 0% in series.[23][41][45]
III. Guideline-Based Selection Criteria and Decision-Making
The choice between DPPHR and PD in chronic pancreatitis with a pancreatic head mass, particularly when imaging and biopsy are inconclusive for malignancy, is guided by a synthesis of clinical, radiologic, and multidisciplinary assessment, as well as current guideline recommendations. The American Society of Clinical Oncology and the American Gastroenterological Association both recommend that surgical decisions be made in a multidisciplinary setting, integrating all available clinical, radiologic, and pathologic data.[6-7][22]
DPPHR is recommended when the probability of malignancy is low or moderate and the primary indication is pain management. This approach is supported by large cohort studies and systematic reviews demonstrating low morbidity and excellent long-term outcomes.[5][9][12-13][23-27] PD is recommended when the probability of malignancy is high, based on clinical, radiologic, or laboratory features, even if biopsy is non-diagnostic. Features that increase suspicion for malignancy include abrupt ductal cutoff, double-duct sign, large mural nodules, marked ductal dilation, vessel encasement, and rapid growth.[7][22][52-55]
IV. Timing of Surgery and Patient-Specific Factors
The timing of surgical intervention and patient-specific factors such as age, comorbidities, and nutritional status significantly influence both the choice of procedure and postoperative outcomes. Early surgery—defined as intervention within a short interval after the onset of opioid-requiring pain and before prolonged medical or endoscopic management—results in superior pain control, improved patient satisfaction, and better early preservation of pancreatic function compared to delayed surgery or an endoscopy-first approach.[18-19][57] The ESCAPE trial demonstrated that early surgery led to lower pain scores, higher rates of complete pain relief, and greater patient satisfaction, with no increase in perioperative risk.[18-19] Delayed surgery is associated with higher risk of exocrine and endocrine insufficiency and less favorable functional outcomes.[57]
Patient-specific factors play a critical role in surgical decision-making. DPPHR is generally preferred in older patients, those with significant comorbidities, poor nutritional status, or limited functional reserve, as it is associated with lower perioperative morbidity, better early preservation of pancreatic function, improved nutritional outcomes, and superior early quality of life.[5][12-13][16][23-26][58] PD is reserved for cases with a high index of suspicion for malignancy, where oncologic completeness is paramount, but carries higher risk of complications and metabolic dysfunction, which may be poorly tolerated in vulnerable patients.[5][12-13][16][23-26][58]
V. Summary and Actionable Recommendations
For patients with chronic pancreatitis and an inflammatory mass in the pancreatic head, without prior pancreatic surgery, the choice of surgical procedure should be individualized based on clinical presentation, imaging findings, and multidisciplinary assessment, with a focus on pain management and oncologic safety.
Duodenum-preserving pancreatic head resection (Beger, Frey, Berne) is the preferred surgical approach for pain management and preservation of pancreatic function in the absence of strong suspicion for malignancy. DPPHR offers equivalent long-term pain relief, exocrine and endocrine function, and quality of life compared to pancreaticoduodenectomy, but with shorter operative times, less blood loss, reduced perioperative morbidity, and better short-term outcomes such as weight gain and occupational rehabilitation. Early surgical intervention (within 6 weeks of opioid-requiring pain) is associated with superior pain control, higher patient satisfaction, and better early preservation of function, without increased perioperative risk.
Pancreaticoduodenectomy remains the operation of choice when malignancy is suspected, offering the highest oncologic safety and lowest recurrence risk, but at the cost of greater functional loss and higher morbidity. When imaging and biopsy are inconclusive for malignancy, guideline-based multidisciplinary assessment is essential, with DPPHR favored when the probability of malignancy is low or moderate, and PD reserved for high clinical suspicion.
Long-term, most patients will develop exocrine and endocrine insufficiency regardless of procedure, but DPPHR delays onset and is associated with lower rates of nutritional deficiencies and better early nutritional outcomes. Routine assessment and management of exocrine insufficiency, early initiation of pancreatic enzyme replacement therapy, and targeted supplementation of vitamins and minerals are essential for all patients undergoing pancreatic head resection.
In summary, for the patient described—chronic pancreatitis with a pancreatic head mass, primary concerns of pain and oncologic outcome, and no prior pancreatic surgery—DPPHR (Beger, Frey, Berne) is the preferred first-line surgical option unless there is strong suspicion of malignancy, in which case PD is indicated. Early surgical intervention is recommended for optimal pain and functional outcomes. All decisions should be made in a multidisciplinary setting, integrating clinical, radiologic, and pathologic data, and tailored to the patient’s comorbidities, nutritional status, and preferences. Regular postoperative monitoring for pancreatic insufficiency and nutritional deficiencies is mandatory, with proactive management to optimize long-term outcomes.
